LT2480552T - 2'-fluoru pakeisti karbanukleozidų analogai, skirti antivirusiniam gydymui - Google Patents
2'-fluoru pakeisti karbanukleozidų analogai, skirti antivirusiniam gydymuiInfo
- Publication number
- LT2480552T LT2480552T LTEP10763083.2T LT10763083T LT2480552T LT 2480552 T LT2480552 T LT 2480552T LT 10763083 T LT10763083 T LT 10763083T LT 2480552 T LT2480552 T LT 2480552T
- Authority
- LT
- Lithuania
- Prior art keywords
- nucleoside analogs
- fluoro substituted
- antiviral treatment
- substituted carba
- carba
- Prior art date
Links
- 230000000840 anti-viral effect Effects 0.000 title 1
- 239000002777 nucleoside Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
- C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
- C07F9/65744—Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems
-
- G—PHYSICS
- G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
- G03C—PHOTOSENSITIVE MATERIALS FOR PHOTOGRAPHIC PURPOSES; PHOTOGRAPHIC PROCESSES, e.g. CINE, X-RAY, COLOUR, STEREO-PHOTOGRAPHIC PROCESSES; AUXILIARY PROCESSES IN PHOTOGRAPHY
- G03C7/00—Multicolour photographic processes or agents therefor; Regeneration of such processing agents; Photosensitive materials for multicolour processes
- G03C7/30—Colour processes using colour-coupling substances; Materials therefor; Preparing or processing such materials
- G03C7/32—Colour coupling substances
- G03C7/36—Couplers containing compounds with active methylene groups
- G03C7/38—Couplers containing compounds with active methylene groups in rings
- G03C7/381—Heterocyclic compounds
- G03C7/382—Heterocyclic compounds with two heterocyclic rings
- G03C7/3825—Heterocyclic compounds with two heterocyclic rings the nuclei containing only nitrogen as hetero atoms
- G03C7/3835—Heterocyclic compounds with two heterocyclic rings the nuclei containing only nitrogen as hetero atoms four nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24429709P | 2009-09-21 | 2009-09-21 | |
| PCT/US2010/049471 WO2011035231A1 (en) | 2009-09-21 | 2010-09-20 | 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT2480552T true LT2480552T (lt) | 2017-02-10 |
Family
ID=43031517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP10763083.2T LT2480552T (lt) | 2009-09-21 | 2010-09-20 | 2'-fluoru pakeisti karbanukleozidų analogai, skirti antivirusiniam gydymui |
Country Status (32)
| Country | Link |
|---|---|
| EP (2) | EP2480552B1 (lt) |
| JP (3) | JP5795766B2 (lt) |
| KR (2) | KR101818779B1 (lt) |
| CN (1) | CN102596958A (lt) |
| AP (1) | AP2012006189A0 (lt) |
| AU (4) | AU2010295373B2 (lt) |
| BR (3) | BR122021021135B1 (lt) |
| CA (1) | CA2773772C (lt) |
| CL (1) | CL2012000707A1 (lt) |
| CR (2) | CR20190103A (lt) |
| CY (1) | CY1118605T1 (lt) |
| DK (1) | DK2480552T3 (lt) |
| EA (1) | EA201200525A1 (lt) |
| EC (1) | ECSP12011817A (lt) |
| ES (2) | ES2730805T3 (lt) |
| HR (1) | HRP20170197T1 (lt) |
| HU (1) | HUE032252T2 (lt) |
| IL (2) | IL218599A (lt) |
| LT (1) | LT2480552T (lt) |
| ME (1) | ME02656B (lt) |
| MX (1) | MX352646B (lt) |
| NZ (1) | NZ599402A (lt) |
| PE (3) | PE20120995A1 (lt) |
| PL (1) | PL2480552T3 (lt) |
| PT (1) | PT2480552T (lt) |
| RS (1) | RS55699B1 (lt) |
| SG (1) | SG179194A1 (lt) |
| SI (1) | SI2480552T1 (lt) |
| SM (1) | SMT201700091B (lt) |
| UA (1) | UA110466C2 (lt) |
| WO (1) | WO2011035231A1 (lt) |
| ZA (1) | ZA201202175B (lt) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA020659B1 (ru) | 2008-04-23 | 2014-12-30 | Джилид Сайэнс, Инк. | 1'-замещённые карбануклеозидные аналоги для противовирусной терапии |
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| EP2376514A2 (en) | 2008-12-23 | 2011-10-19 | Pharmasset, Inc. | Nucleoside analogs |
| AR074897A1 (es) | 2008-12-23 | 2011-02-23 | Pharmasset Inc | Fosforamidatos de nucleosidos |
| PA8855801A1 (es) | 2008-12-23 | 2010-07-27 | Sintesis de nucleosidos de purina | |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| MX2012003126A (es) * | 2009-09-21 | 2012-06-19 | Gilead Sciences Inc | Procesos e intermedios para la preparacion de analogos de 1'-carbonucleosidos sustituidos. |
| US7973013B2 (en) * | 2009-09-21 | 2011-07-05 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
| CA2773772C (en) * | 2009-09-21 | 2018-06-26 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
| US8455451B2 (en) | 2009-09-21 | 2013-06-04 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
| US8859756B2 (en) * | 2010-03-31 | 2014-10-14 | Gilead Pharmasset Llc | Stereoselective synthesis of phosphorus containing actives |
| TW201201815A (en) * | 2010-05-28 | 2012-01-16 | Gilead Sciences Inc | 1'-substituted-carba-nucleoside prodrugs for antiviral treatment |
| AP2013006665A0 (en) | 2010-07-19 | 2013-01-31 | Gilead Sciences Inc | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
| MX2013000744A (es) | 2010-07-22 | 2013-03-07 | Gilead Sciences Inc | Metodos y compuestos para tratar infecciones virales por paramyxoviridae. |
| TW201305185A (zh) * | 2010-09-13 | 2013-02-01 | Gilead Sciences Inc | 用於抗病毒治療之２’－氟取代之碳－核苷類似物 |
| AP3699A (en) * | 2010-09-20 | 2016-05-31 | Gilead Sciences Inc | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
| CN103491948B (zh) | 2010-11-19 | 2016-11-02 | 吉利德科学公司 | 包含利匹韦林HCl和富马酸替诺福韦酯的治疗组合物 |
| WO2012087596A1 (en) | 2010-12-20 | 2012-06-28 | Gilead Sciences, Inc. | Combinations for treating hcv |
| EP2755983B1 (en) | 2011-09-12 | 2017-03-15 | Idenix Pharmaceuticals LLC. | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections |
| KR101991298B1 (ko) | 2011-09-16 | 2019-06-21 | 길리애드 파마셋 엘엘씨 | Hcv 치료 방법 |
| WO2013056046A1 (en) | 2011-10-14 | 2013-04-18 | Idenix Pharmaceuticals, Inc. | Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| EP3210993B1 (en) * | 2012-03-13 | 2018-12-12 | Gilead Sciences, Inc. | 2'- substituted carba-nucleoside analogs for antiviral treatment |
| US9242988B2 (en) | 2012-10-17 | 2016-01-26 | Merck Sharp & Dohme Corp. | 2′-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| US9457039B2 (en) | 2012-10-17 | 2016-10-04 | Merck Sharp & Dohme Corp. | 2′-disubstituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| AR092959A1 (es) | 2012-10-17 | 2015-05-06 | Merck Sharp & Dohme | Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales |
| RU2015123641A (ru) | 2012-11-19 | 2017-01-10 | Мерк Шарп И Доум Корп. | 2-алкинилзамещенные производные нуклеозидов, предназначенные для лечения вирусных заболеваний |
| WO2014120981A1 (en) | 2013-01-31 | 2014-08-07 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
| US9765107B2 (en) | 2013-06-18 | 2017-09-19 | Merck Sharp & Dohme Corp. | Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| UA119050C2 (uk) | 2013-11-11 | 2019-04-25 | Ґілеад Саєнсиз, Інк. | ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ |
| US10683321B2 (en) | 2013-12-18 | 2020-06-16 | Idenix Pharmaceuticals Llc | 4′-or nucleosides for the treatment of HCV |
| TWI678369B (zh) | 2014-07-28 | 2019-12-01 | 美商基利科學股份有限公司 | 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類 |
| WO2016023522A2 (en) | 2014-08-15 | 2016-02-18 | Merck Sharp & Dohme Corp. | Substituted phosphoramidate compounds and uses thereof |
| TWI673283B (zh) | 2014-08-21 | 2019-10-01 | 美商基利科學股份有限公司 | ２’－氯胺基嘧啶酮及嘧啶二酮核苷類 |
| TWI767201B (zh) | 2014-10-29 | 2022-06-11 | 美商基利科學股份有限公司 | 絲狀病毒科病毒感染之治療 |
| EP3236972B1 (en) | 2014-12-26 | 2021-07-28 | Emory University | Anti-viral n4-hydroxycytidine derivatives |
| WO2016160646A1 (en) | 2015-04-02 | 2016-10-06 | Merck Sharp & Dohme Corp. | Process for making phosphoramidate protected nucleoside compounds |
| CN104945437B (zh) * | 2015-05-19 | 2017-03-01 | 广州诺威生物技术有限公司 | 一种嘧啶类新化合物 |
| MA42819A (fr) | 2015-09-16 | 2018-07-25 | Gilead Sciences Inc | Procédés pour le traitement d'infections virales à arenaviridae et coronaviridae |
| WO2017156262A1 (en) | 2016-03-09 | 2017-09-14 | Alios Biopharma, Inc. | Acyclic antivirals |
| TWI828027B (zh) | 2016-03-28 | 2024-01-01 | 美商英塞特公司 | 作為tam抑制劑之吡咯并三嗪化合物 |
| CN106083962B (zh) * | 2016-06-08 | 2018-12-18 | 成都倍特药业有限公司 | 一种具有环磷酰胺结构的化合物及其制备方法 |
| US10202412B2 (en) | 2016-07-08 | 2019-02-12 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections |
| CN109476668B (zh) * | 2016-07-14 | 2022-03-22 | 豪夫迈·罗氏有限公司 | 用于治疗感染性疾病的6,7-二氢-4H-吡唑并[1,5-a]吡嗪和6,7-二氢-4H-***并[1,5-a]吡嗪化合物 |
| CN109890831A (zh) * | 2016-08-12 | 2019-06-14 | 詹森生物制药有限公司 | 被取代的核苷、核苷酸以及它们的类似物 |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| TW201836615A (zh) | 2017-03-14 | 2018-10-16 | 美商基利科學股份有限公司 | 治療貓冠狀病毒感染之方法 |
| AU2018262501B2 (en) | 2017-05-01 | 2020-12-10 | Gilead Sciences, Inc. | Crystalline forms of (S) 2 ethylbutyl 2 (((S) (((2R,3S,4R,5R) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate |
| US10675296B2 (en) | 2017-07-11 | 2020-06-09 | Gilead Sciences, Inc. | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
| CA3082191C (en) | 2017-12-07 | 2021-09-21 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| US10836769B2 (en) | 2018-02-26 | 2020-11-17 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
| CA3129234A1 (en) * | 2019-02-07 | 2020-08-13 | Beigene, Ltd. | Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as tlr7 agonist |
| CA3137119A1 (en) | 2019-05-09 | 2020-11-12 | Aligos Therapeutics, Inc. | Modified cyclic dinucleoside compounds as sting modulators |
| TWI789695B (zh) | 2020-01-27 | 2023-01-11 | 美商基利科學股份有限公司 | 治療sars cov-2感染之方法 |
| US20210292348A1 (en) | 2020-02-18 | 2021-09-23 | Gilead Sciences, Inc. | Antiviral compounds |
| TW202322824A (zh) | 2020-02-18 | 2023-06-16 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI791193B (zh) | 2020-02-18 | 2023-02-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI785528B (zh) | 2020-03-12 | 2022-12-01 | 美商基利科學股份有限公司 | 1’-氰基核苷之製備方法 |
| EP4132651A1 (en) | 2020-04-06 | 2023-02-15 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
| EP4157272A1 (en) | 2020-05-29 | 2023-04-05 | Gilead Sciences, Inc. | Remdesivir treatment methods |
| BR112022026321A2 (pt) | 2020-06-24 | 2023-01-17 | Gilead Sciences Inc | Análogos de 1'-ciano nucleosídeo e usos dos mesmos |
| US11926645B2 (en) | 2020-08-27 | 2024-03-12 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
| EP4323064A1 (en) * | 2021-04-14 | 2024-02-21 | Yeda Research and Development Co. Ltd | Anti-viral and anti-tumoral compounds, and uses thereof |
| CA3216162A1 (en) | 2021-04-16 | 2022-10-20 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
| EP4337323A1 (en) * | 2021-05-14 | 2024-03-20 | BM Pharma Consulting Pty. Ltd | Bicyclic heterocyclic compounds for prophylaxis and treatment of viral infections |
| TW202400185A (zh) | 2022-03-02 | 2024-01-01 | 美商基利科學股份有限公司 | 用於治療病毒感染的化合物及方法 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816570A (en) | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
| US4968788A (en) | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
| AU651835B2 (en) | 1990-06-13 | 1994-08-04 | Arnold Glazier | Phosphorous prodrugs |
| DE69129650T2 (de) | 1990-09-14 | 1999-03-25 | Acad Of Science Czech Republic | Wirkstoffvorläufer von Phosphonaten |
| US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| DE19912636A1 (de) | 1999-03-20 | 2000-09-21 | Aventis Cropscience Gmbh | Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel |
| WO2001032153A2 (en) | 1999-11-04 | 2001-05-10 | Shire Biochem Inc. | Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues |
| PL364995A1 (en) | 2000-02-18 | 2004-12-27 | Shire Biochem Inc. | Method for the treatment or prevention of flavivirus |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
| ATE491459T1 (de) | 2000-10-18 | 2011-01-15 | Pharmasset Inc | Modifizierte nukleoside zur behandlung von virusinfektionen und abnormaler zellulärer proliferation |
| AU2002243791B2 (en) * | 2001-01-22 | 2006-06-29 | Isis Pharmaceuticals, Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
| EP1438054A4 (en) | 2001-09-28 | 2006-07-26 | Idenix Cayman Ltd | METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUS AND PESTIVIRUS USING MODIFIED NUCLEOSIDE AT 4 'POSITION |
| DK1576138T3 (en) | 2002-11-15 | 2017-05-01 | Idenix Pharmaceuticals Llc | 2'-METHYL NUCLEOSIDES IN COMBINATION WITH INTERFERON AND FLAVIVIRIDAE MUTATION |
| RU2433124C2 (ru) | 2004-09-14 | 2011-11-10 | Фармассет, Инк. | Способ получения 2'-фтор-2'-алкилзамещенных или других замещенных рибофуранозилпиримидинов и пуринов и их производных |
| CN101043893A (zh) * | 2004-10-21 | 2007-09-26 | 默克公司 | 治疗RNA－依赖性RNA病毒感染的氟化吡咯并[2,3－d]嘧啶核苷 |
| WO2006065335A2 (en) * | 2004-10-21 | 2006-06-22 | Merck & Co., Inc. | Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection |
| TW200720285A (en) * | 2005-04-25 | 2007-06-01 | Genelabs Tech Inc | Nucleoside compounds for treating viral infections |
| WO2006121820A1 (en) | 2005-05-05 | 2006-11-16 | Valeant Research & Development | Phosphoramidate prodrugs for treatment of viral infection |
| WO2007027248A2 (en) | 2005-05-16 | 2007-03-08 | Valeant Research & Development | 3', 5' - cyclic nucleoside analogues for treatment of hcv |
| WO2007056170A2 (en) | 2005-11-02 | 2007-05-18 | Bayer Healthcare Ag | Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases |
| US7842672B2 (en) * | 2006-07-07 | 2010-11-30 | Gilead Sciences, Inc. | Phosphonate inhibitors of HCV |
| US20080261913A1 (en) * | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
| CA2673649A1 (en) | 2007-01-05 | 2008-07-17 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
| EP2535345A1 (en) * | 2007-01-12 | 2012-12-19 | BioCryst Pharmaceuticals, Inc. | Anticancer nucleoside analogs |
| EP2125819B1 (en) | 2007-03-21 | 2014-10-22 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases |
| ES2393038T3 (es) | 2007-05-10 | 2012-12-18 | Biocryst Pharmaceuticals, Inc. | Compuestos de tretrahidrofuro[3,4-D]dioxolano para su utlilización en el tratamiento de las infecciones víricas y del cáncer |
| US8227431B2 (en) * | 2008-03-17 | 2012-07-24 | Hetero Drugs Limited | Nucleoside derivatives |
| EA020659B1 (ru) | 2008-04-23 | 2014-12-30 | Джилид Сайэнс, Инк. | 1'-замещённые карбануклеозидные аналоги для противовирусной терапии |
| EP2313102A2 (en) | 2008-07-03 | 2011-04-27 | Biota Scientific Management | Bycyclic nucleosides and nucleotides as therapeutic agents |
| MX2012003126A (es) * | 2009-09-21 | 2012-06-19 | Gilead Sciences Inc | Procesos e intermedios para la preparacion de analogos de 1'-carbonucleosidos sustituidos. |
| CA2773772C (en) * | 2009-09-21 | 2018-06-26 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
-
2010
- 2010-09-20 CA CA2773772A patent/CA2773772C/en active Active
- 2010-09-20 HU HUE10763083A patent/HUE032252T2/en unknown
- 2010-09-20 SI SI201031372T patent/SI2480552T1/sl unknown
- 2010-09-20 JP JP2012529958A patent/JP5795766B2/ja active Active
- 2010-09-20 NZ NZ599402A patent/NZ599402A/en unknown
- 2010-09-20 UA UAA201204937A patent/UA110466C2/ru unknown
- 2010-09-20 CR CR20190103A patent/CR20190103A/es unknown
- 2010-09-20 PE PE2012000359A patent/PE20120995A1/es not_active Application Discontinuation
- 2010-09-20 KR KR1020127010076A patent/KR101818779B1/ko active IP Right Grant
- 2010-09-20 EA EA201200525A patent/EA201200525A1/ru unknown
- 2010-09-20 BR BR122021021135-3A patent/BR122021021135B1/pt active IP Right Grant
- 2010-09-20 PL PL10763083T patent/PL2480552T3/pl unknown
- 2010-09-20 MX MX2012003391A patent/MX352646B/es active IP Right Grant
- 2010-09-20 EP EP10763083.2A patent/EP2480552B1/en active Active
- 2010-09-20 LT LTEP10763083.2T patent/LT2480552T/lt unknown
- 2010-09-20 PE PE2016000070A patent/PE20160217A1/es unknown
- 2010-09-20 PE PE2020000354A patent/PE20210668A1/es unknown
- 2010-09-20 ME MEP-2017-35A patent/ME02656B/me unknown
- 2010-09-20 BR BR112012006261-1A patent/BR112012006261B1/pt active IP Right Grant
- 2010-09-20 ES ES16196457T patent/ES2730805T3/es active Active
- 2010-09-20 WO PCT/US2010/049471 patent/WO2011035231A1/en active Application Filing
- 2010-09-20 AU AU2010295373A patent/AU2010295373B2/en active Active
- 2010-09-20 EP EP16196457.2A patent/EP3150608B1/en active Active
- 2010-09-20 RS RS20170152A patent/RS55699B1/sr unknown
- 2010-09-20 BR BR122021012877A patent/BR122021012877B8/pt active IP Right Grant
- 2010-09-20 AP AP2012006189A patent/AP2012006189A0/xx unknown
- 2010-09-20 KR KR1020187000491A patent/KR20180006499A/ko not_active Application Discontinuation
- 2010-09-20 DK DK10763083.2T patent/DK2480552T3/en active
- 2010-09-20 ES ES10763083.2T patent/ES2614651T3/es active Active
- 2010-09-20 PT PT107630832T patent/PT2480552T/pt unknown
- 2010-09-20 SG SG2012018883A patent/SG179194A1/en unknown
- 2010-09-20 CN CN201080041902XA patent/CN102596958A/zh active Pending
-
2012
- 2012-03-13 IL IL218599A patent/IL218599A/en active IP Right Grant
- 2012-03-21 CL CL2012000707A patent/CL2012000707A1/es unknown
- 2012-03-23 ZA ZA2012/02175A patent/ZA201202175B/en unknown
- 2012-04-17 CR CR20120186A patent/CR20120186A/es unknown
- 2012-04-19 EC ECSP12011817 patent/ECSP12011817A/es unknown
-
2015
- 2015-05-14 JP JP2015098728A patent/JP6033362B2/ja active Active
-
2016
- 2016-09-28 IL IL248110A patent/IL248110A0/en unknown
- 2016-10-24 JP JP2016207475A patent/JP2017075146A/ja not_active Withdrawn
- 2016-11-23 AU AU2016262676A patent/AU2016262676B2/en active Active
-
2017
- 2017-02-07 CY CY20171100168T patent/CY1118605T1/el unknown
- 2017-02-07 HR HRP20170197TT patent/HRP20170197T1/hr unknown
- 2017-02-09 SM SM201700091T patent/SMT201700091B/it unknown
-
2018
- 2018-06-20 AU AU2018204449A patent/AU2018204449B2/en active Active
-
2020
- 2020-04-17 AU AU2020202600A patent/AU2020202600B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170197T1 (hr) | 2' -fluoro supstituirani karba-nukleozidni analozi za antiviralno liječenje | |
| HUS2000055I1 (hu) | 1'-szubsztituált carba-nukleozid analógok antivirális kezelésre | |
| AP3699A (en) | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment | |
| AP2922A (en) | Carbra-nucleoside analogs for antiviral treatment | |
| ME01882B (me) | 1 '-supstituisani-karba-nukleozidni prolekovi za antivirusni tretman |